1. Home
  2. ANGH vs LNAI Comparison

ANGH vs LNAI Comparison

Compare ANGH & LNAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Anghami Inc.

ANGH

Anghami Inc.

HOLD

Current Price

$4.15

Market Cap

22.1M

ML Signal

HOLD

Logo Lunai Bioworks Inc.

LNAI

Lunai Bioworks Inc.

N/A

Current Price

$0.92

Market Cap

23.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ANGH
LNAI
Founded
2012
N/A
Country
United Arab Emirates
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.1M
23.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ANGH
LNAI
Price
$4.15
$0.92
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
2.2M
281.4K
Earning Date
04-30-2026
02-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$96,736,848.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
85.06
N/A
52 Week Low
$2.25
$0.81
52 Week High
$8.40
$14.00

Technical Indicators

Market Signals
Indicator
ANGH
LNAI
Relative Strength Index (RSI) 79.17 N/A
Support Level $2.30 N/A
Resistance Level $2.71 N/A
Average True Range (ATR) 0.30 0.00
MACD 0.16 0.00
Stochastic Oscillator 98.97 0.00

Price Performance

Historical Comparison
ANGH
LNAI

About ANGH Anghami Inc.

Anghami Inc is a digital music entertainment technology platform in the Middle East and North Africa, with a catalog of songs. The company features licensed content from Arabic labels, independent artists, and distributors. It also features music from International labels such as Universal, Sony, and Warner Music. It generates the majority of its revenue from subscriptions.

About LNAI Lunai Bioworks Inc.

Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.

Share on Social Networks: